Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

Research & information: general --- Chemistry --- positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules --- positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules --- n/a